Defining drug response for stratified medicine

Mike Lonergan, Stephen J. Senn, Christine McNamee, Ann K. Daly, Robert Sutton, Andrew Hattersley, Ewan Pearson, Munir Pirmohamed (Lead / Corresponding author)

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.

Original languageEnglish
Pages (from-to)173-179
Number of pages7
JournalDrug Discovery Today
Volume22
Issue number1
Early online date3 Nov 2016
DOIs
Publication statusPublished - Jan 2017

Fingerprint Dive into the research topics of 'Defining drug response for stratified medicine'. Together they form a unique fingerprint.

  • Cite this

    Lonergan, M., Senn, S. J., McNamee, C., Daly, A. K., Sutton, R., Hattersley, A., Pearson, E., & Pirmohamed, M. (2017). Defining drug response for stratified medicine. Drug Discovery Today, 22(1), 173-179. https://doi.org/10.1016/j.drudis.2016.10.016